To meet the rising demand for patient-pleasant and secure options for drug administration, the drug developers are anticipated to broader their portfolio of drug candidates to make them favorable for delivery by means of self-injection methods. We identified several parameters which impact the probability of the drug to be delivered by way of the huge volume wearable injectors. These incorporate the drug’s volume and dosage, dose frequency, dose variety, route of administration, target ailment indication and yr of patent expiry (in situation of marketed medicines).



An evaluation of above 800 marketed and pipeline drugs unveiled that, presently, there are shut to 200 molecules that have demonstrated the prospective to be delivered by way of huge volume wearable injectors. Of these, 90% are biologics and 10% are modest molecules. In truth, in an interview with the chief executive officer of a US-based mostly healthcare gadget business, he stated that “There is significant possibility of these products for the delivery of each biologics and modest molecules. I think that, drug gadget compatibility depends on the desired release pattern. Such device can be properly utilised for the delivery of medication for which timed release is necessary. ”




Based on our proprietary scoring criteria, subcutaneously delivered medicines have the highest probability to be administered via the large volume injectors. Self-subcutaneous route of administration is well accepted by the individuals whereas IV infusion has to be completed in a hospital setting.  Moreover, bulk of the large volume wearable injectors have been created with the needle / cannula systems which can penetrate the epidermis to deliver the drug to the subcutaneous capillary and lymphatic vessels in which it is readily absorbed. Additional, a quantity of medication are very likely to drop advertising exclusivity due to patent expiry in the coming years. This paves the way for the entry of a massive quantity of biosimilars which are reformulated to be administered by way of the subcutaneous route, presenting extra opportunities for the development of the large volume wearable injectors marketplace.



site Further, the examination uncovered that medication made for particular clinical conditions, such as neurological issues, oncological problems, discomfort management, reproductive disorders and metabolic issues, are most ideal for administration with huge volume wearable injectors. Interestingly, numerous drug gadget combinations are already currently being created / marketed for the aforementioned indications, at present. Notable examples include (in alphabetical order, no selection criteria) D-mine Pump (EVER Pharma / Sensile Medical), Lutrepulse Technique (Insulet / Ferring Pharmaceuticals) and Pushtronex Method (Amgen / West Pharmaceutical Solutions).